IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

Journal of Clinical Investigation

Volumn 129, Issue 9, 2019, Pages 3625-3639

  Channappanavar, Rudragouda ^a,b,c   Fehr, Anthony R ^a,g   Zheng, Jian ^a   Wohlford Lenane, Christine ^a   Abrahante, Juan E ^d   Mack, Matthias ^e   Sompallae, Ramakrishna ^a   McCray, Paul B ^a   Meyerholz, David K ^a   Perlman, Stanley ^a,f  

^a UNIVERSITY OF IOWA   (United States)

^b 701E Molecular Sciences Building   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^f GUANGZHOU MEDICAL UNIVERSITY   (China)

^g UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; BETA INTERFERON; CYTOSOL RECEPTOR; GENOMIC RNA; INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; PATTERN RECOGNITION RECEPTOR; PROSTAGLANDIN E RECEPTOR; SIRTUIN 1; TOLL LIKE RECEPTOR 7; CYTOKINE;

AIRWAY EPITHELIUM CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CELL ACTIVATION; CELL INFILTRATION; CLINICAL OUTCOME; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE EXACERBATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEMATOPOIETIC CELL; HISTOLOGY; HUMAN ADENOVIRUS 5; INNATE IMMUNITY; LD50; LUNG; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MONOCYTE; MORTALITY RATE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; T LYMPHOCYTE; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; CELL SEPARATION; CORONAVIRUS INFECTION; CYTOLOGY; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; MALE; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL SEPARATION; CORONAVIRUS INFECTIONS; CYTOKINES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELLS; HUMANS; INFLAMMATION; INTERFERON-BETA; LUNG; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MONOCYTES; NEUTROPHILS; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

EID: 85070807480     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI126363     Document Type: Article

References (72)

1. Bloom DE, Black S, Rappuoli R. Emerging infectious diseases: a proactive approach. Proc Natl Acad Sci U S A. 2017;114(16):4055-4059.
2. Assiri A, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369(5):407-416.
3. Peiris JS, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361(9366):1319-1325.
4. Su S, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490-502.
5. Assiri A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752-761.
6. Middle East respiratory syndrome coronavirus (MERS-CoV). World Health Organization web site. http://www.who.int/emergencies/mers-cov/en/. Updated September 21, 2018. Accessed June 14, 2019.
7. Menachery VD, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2015;21(12):1508-1513.
8. Ge XY, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503(7477):535-538.
9. de Wit E, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A. 2013;110(41):16598-16603.
10. Li K, et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci U S A. 2017;114(15):E3119-E3128.
11. Cockrell AS, et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol. 2016;2:16226.
12. Baseler LJ, et al. An acute immune response to Middle East respiratory syndrome coronavirus replication contributes to viral pathogenicity. Am J Pathol. 2016;186(3):630-638.
13. van den Brand JM, Haagmans BL, van Riel D, Osterhaus AD, Kuiken T. The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. J Comp Pathol. 2014;151(1):83-112.
14. Channappanavar R, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181-193.
15. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513-545.
16. Totura AL, Baric RS. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol. 2012;2(3):264-275.
17. Omrani AS, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090-1095.
18. Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther (Lond). 2016;21(5):455-459.
19. Loutfy MR, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003;290(24):3222-3228.
20. Gao L, et al. A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine. 2010;28(28):4445-4451.
21. Davidson S, Crotta S, McCabe TM, Wack A. Pathogenic potential of interferon αβ in acute influenza infection. Nat Commun. 2014;5:3864.
22. Davidson S, Maini MK, Wack A. Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. J Interferon Cytokine Res. 2015;35(4):252-264.
23. Wilson EB, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science. 2013;340(6129):202-207.
24. Teijaro JR, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science. 2013;340(6129):207-211.
25. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoSMed. 2006;3(9):e343.
26. Shalhoub S, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother. 2015;70(7):2129-2132.
27. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis. 2014;20:42-46.
28. Cervantes-Barragan L, et al. Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. Blood. 2007;109(3):1131-1137.
29. Roth-Cross JK, Bender SJ, Weiss SR. Murine coronavirus mouse hepatitis virus is recognized by MDA5 and induces type I interferon in brain macrophages/microglia. J Virol. 2008;82(20):9829-9838.
30. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol. 2002;168(2):554-561.
31. Ioannidis I, Ye F, McNally B, Willette M, Flaño E. Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J Virol. 2013;87(6):3261-3270.
32. Zielecki F, et al. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared with those of severe acute respiratory syndrome coronavirus. J Virol. 2013;87(9):5300-5304.
33. Peiris JS. Severe acute respiratory syndrome (SARS). J Clin Virol. 2003;28(3):245-247.
34. Franks TJ, et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum Pathol. 2003;34(8):743-748.
35. Ng DL, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol. 2016;186(3):652-658.
36. Zhao J, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A. 2014;111(13):4970-4975.
37. Kaner RJ, et al. Modification of the genetic program of human alveolar macrophages by adenovirus vectors in vitro is feasible but inefficient, limited in part by the low level of expression of the coxsackie/adenovirus receptor. Am J Respir Cell Mol Biol. 1999;20(3):361-370.
38. Law HK, et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005;106(7):2366-2374.
39. Cheung CY, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol. 2005;79(12):7819-7826.
40. Gu J, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415-424.
41. Nicholls JM, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361(9371):1773-1778.
42. Cervantes-Barragán L, et al. Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. J Immunol. 2009;182(2):1099-1106.
43. Koestner W, et al. Interferon-beta expression and type I interferon receptor signaling of hepatocytes prevent hepatic necrosis and virus dissemination in Coxsackievirus B3-infected mice. PLoS Pathog. 2018;14(8):e1007235.
44. Monto AS, Albrecht JK, Schwartz SA. Demonstration of dose-response relationship in seasonal prophylaxis of respiratory infections with alpha-2b interferon. Antimicrob Agents Chemother. 1988;32(1):47-50.
45. Farr BM, Gwaltney JM, Adams KF, Hayden FG. Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds. Antimicrob Agents Chemother. 1984;26(1):31-34.
46. Kim ES, et al. Clinical progression and cytokine profiles of Middle East respiratory syndrome coronavirus infection. J Korean Med Sci. 2016;31(11):1717-1725.
47. Min CK, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep. 2016;6:25359.
48. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med. 2005;202(5):637-650.
49. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol. 2005;174(8):4465-4469.
50. Zhao J, Zhao J, Legge K, Perlman S. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J Clin Invest. 2011;121(12):4921-4930.
51. Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010;84(18):9318-9325.
52. Coleman CM, et al. CD8+ T cells and macrophages regulate pathogenesis in a mouse model of Middle East respiratory syndrome. J Virol. 2017;91(1):e01825-16.
53. Seo SU, et al. Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils during acute viral pneumonia in mice. PLoS Pathog. 2011;7(2):e1001304.
54. Tynell J, et al. Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells. J Gen Virol. 2016;97(2):344-355.
55. Zhou J, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis. 2014;209(9):1331-1342.
56. Chu H, et al. Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J Infect Dis. 2016;213(6):904-914.
57. Scheuplein VA, et al. High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus. J Virol. 2015;89(7):3859-3869.
58. Bang FB, Warwick A. Mouse macrophages as host cells for the mouse hepatitis virus and the genetics basis of their susceptibility. Proc Natl Acad Sci U S A. 1960;46(8):1065-1075.
59. Kantoch M, Warwick A, Bang FB. The cellular nature of genetic susceptibility to a virus. J Exp Med. 1963;117:781-798.
60. Koyama S, et al. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J Immunol. 2007;179(7):4711-4720.
61. Goritzka M, et al. Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes. J Exp Med. 2015;212(5):699-714.
62. Siu KL, et al. Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. J Virol. 2014;88(9):4866-4876.
63. Gralinski LE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio. 2018;9(5):e01753-18.
64. Wang Y, et al. Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe. 2012;11(6):631-642.
65. Davidson S, et al. IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBOMol Med. 2016;8(9):1099-1112.
66. Falzarano D, et al. Treatment with interferonα2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313-1317.
67. Khalid M, Al Rabiah F, Khan B, Al Mobeireek A, Butt TS, Al Mutairy E. Ribavirin and interferonα2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases. Antivir Ther (Lond). 2015;20(1):87-91.
68. Meyerholz DK, Beck AP. Principles and approaches for reproducible scoring of tissue stains in research. Lab Invest. 2018;98(7):844-855.
69. Mack M, et al. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J Immunol. 2001;166(7):4697-4704.
70. Zhou H, Zhao J, Perlman S. Autocrine interferon priming in macrophages but not dendritic cells results in enhanced cytokine and chemokine production after coronavirus infection. MBio. 2010;1(4):e00219-10.
71. Lee PY, et al. Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. Am J Pathol. 2009;175(5):2023-2033.
72. Zhao J, et al. Intranasal treatment with poly(I•C) protects aged mice from lethal respiratory virus infections. J Virol. 2012;86(21):11416-11424.